RHY Shares Rhythm Biosciences Limited
ASX · ASXLast in our picks 2026-10-17 — not in the current list; analysis below is from that screen
Early-stage therapeutics pipeline offers asymmetric upside but requires clinical validation and funding discipline.
Signal breakdown
- ▸Pipeline updates are the primary potential re-rating catalyst.
- ▾Below 50-day MA (-17.16%)
- ▸Volume 3.51× average — accumulation
- ▾Near 52-week low (4.5% of range)
Is RHY a buy right now?
Trend: RHY is trading below the 50-day average (-18.75%), RSI 36 — neutral momentum, with a 3-month return of -16.67%.
Valuation & quality: Rhythm Biosciences Limited trades on price-to-book 6.50; fundamentals show net margin 0.0%, return on equity -276.0%, revenue growth -25.9% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.54 (+723.1% vs the last close; range A$0.54 – A$0.54), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Early-stage therapeutics pipeline offers asymmetric upside but requires clinical validation and funding discipline.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -13.60% | -26.30% | -14.30% | -25.00% | -11.10% | +12.50% | -11.10% | -25.00% |
Fundamentals
Analyst price target
Technical signals
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States.
Sector: Healthcare · Industry: Diagnostics & Research · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.